| 董 倩,姜 达,姚孜琪.cNCCN指南对Her-2过表达型乳腺癌治疗的指导意义[J].中国肿瘤,2015,24(8):688-695. |
| cNCCN指南对Her-2过表达型乳腺癌治疗的指导意义 |
| The Guiding Significance of cNCCN Guidelines for the Treatment of Her-2 Over-Expressing Breast Cancer |
| 投稿时间：2014-10-30 |
| DOI：10.11735/j.issn.1004-0242.2015.08.A013 |
|
 |
| 中文关键词: Her-2过表达型乳腺癌 临床特点 cNCCN 预后 赫塞汀 |
| 英文关键词:Her-2 over-expressing breast cancer clinical characteristics cNCCN prognosis Herceptin |
| 基金项目: |
|
| 摘要点击次数: 2020 |
| 全文下载次数: 962 |
| 中文摘要: |
| 摘 要：［目的］ 总结在cNCCN指导下的Her-2过表达型乳腺癌的临床特征、诊疗现状及相应预后；判定cNCCN指南对于Her-2过表达型乳腺癌临床治疗的指导价值。［方法］ 回顾性分析具有明确病理学诊断的530例Her-2过表达型乳腺癌患者资料，并进行预后因素分析。［结果］ 根据2007～2011各年cNCCN乳腺癌临床实践指南，紫杉类药物规范治疗组较非规范治疗组的OS延长(49.379个月 vs 2.087个月，P=0.024)；而蒽环类规范治疗组与非规范治疗组的PFS及OS无统计学差异。对于AJCC分期Ⅲ期Her-2过表达型乳腺癌患者，紫杉规范治疗组较蒽环规范治疗组PFS明显延长(49.875个月 vs 31.594个月，P=0.036)，而两组之间的OS无统计学差异(P=0.369)；AJCCⅠ期，Ⅱ期，Ⅳ期及淋巴结阴性的紫杉规范治疗组与蒽环规范治疗组的PFS及OS无统计学差异(P<0.05)。规范放疗组较非规范放疗组延长了OS(54.360个月vs 45.927个月，P=0.044)；赫塞汀规范治疗组较非规范治疗组的延长了PFS(66.758个月vs 52.863个月，P=0.027)，但OS无统计学意义(P=0.059)。［结论］ 对于Her-2过表达型乳腺癌，规范的紫杉醇类化疗方案、规范放疗可延长患者的总生存，而赫塞汀规范应用可改善其无病生存期。 |
| 英文摘要: |
| Abstract：［Purpose］ To summarized the clinical characteristics，treatment status and prognosis for breast cancer with Her-2 over-expression underling the cNCCN Guideline，and to determine the value of cNCCN Guideline on the therapy of breast cancer with Her-2 over-expression.［Methods］ The clinical date of 530 cases with breast cancer with Her-2 over-expression pathologically proven were analyzed retrospectively. The prognostic factors of breast cancer with Her-2 over-expression were analyzed.［Results］ According to the cNCCN breast cancer clinical practice guidelines of 2007~2011，patients who received standard taxane-based therapy had significantly longer OS compared with nonstandard taxane-based therapy group（49.379 months vs 2.087 months，P=0.024. The PFS and OS of patients with standard anthracycline-based therapy were not prolonged than those who had nonstandard anthracycline-based therapy. In AJCC stage Ⅲ patients，the PFS of standard taxane-based therapy group was significantly longer than standard anthracycline-based therapy group (49.875 months vs 31.594 months，P=0.036)，but OS was no difference(P=0.369). And in AJCC stage Ⅰ，Ⅱ，Ⅳ and lymph node negative patients，there were no differences of PFS and OS between the two groups(P=0.059). The standard radiotherapy was improved survival compared with non-standard radiotherapy (54.360 months vs 45.927 months，P=0.044). Standard herceptin-based therapy group had significantly longer PFS compared with non-standard herceptin-based therapy group (66.758 months vs 52.863 months，P=0.027)，but OS was no difference(P=0.059). ［Conclusion］ For breast cancer patients with Her-2 over expressing，the standard taxane-based therapy and radiotherapy improve OS，and the PFS is improved in the standard herceptin-based therapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |